This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Simulations Plus (SLP), Incyte (INCY) and Glaukos (GKOS)

Tipranks - Tipranks - Thu Jun 18, 5:50AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Simulations Plus (SLP), Incyte (INCY) and Glaukos (GKOS).

Claim 55% Off TipRanks

Simulations Plus (SLP)

In a report released yesterday, David Larsen from BTIG assigned a Hold rating to Simulations Plus, with a price target of $18.50. The company’s shares closed last Tuesday at $18.24.

According to TipRanks.com, Larsen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.7% and a 35.1% success rate. Larsen covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Definitive Healthcare Corp, and Lifestance Health Group. ;'>

Currently, the analyst consensus on Simulations Plus is a Hold with an average price target of $17.25, a -5.2% downside from current levels. In a report released today, William Blair also downgraded the stock to Hold.

See today’s best-performing stocks on TipRanks >>

Incyte (INCY)

In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on Incyte, with a price target of $101.00. The company’s shares closed last Tuesday at $99.75.

According to TipRanks.com, Archila is a 5-star analyst with an average return of 18.5% and a 53.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Kyverna Therapeutics, Inc., and Monte Rosa Therapeutics. ;'>

Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $111.13, implying an 8.2% upside from current levels. In a report issued on June 8, William Blair also maintained a Hold rating on the stock.

Glaukos (GKOS)

In a report released today, David Saxon from Needham maintained a Buy rating on Glaukos, with a price target of $150.00. The company’s shares closed last Tuesday at $127.53.

According to TipRanks.com, Saxon is a 1-star analyst with an average return of -1.8% and a 34.0% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Irhythm Technologies, and Alphatec Holdings. ;'>

Glaukos has an analyst consensus of Strong Buy, with a price target consensus of $157.50, implying a 20.5% upside from current levels. In a report issued on June 3, William Blair also maintained a Buy rating on the stock.

Read More on SLP:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).